Resurfacing an August report: Marico's Q1 FY26 revenue rose 23.3% as India business grew 27.2%
In results reported in early August, Marico posted Q1 FY26 consolidated net profit of Rs 513 crore, up 8.2% year on year, on revenue from operations of Rs 3,259 crore. India revenue grew 27.2% while international revenue rose 12.9%; the company also increased its stake in Plix maker Satiya Nutraceuticals to 60%.
What happened
Marico reported Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by 27.2% growth in India. The company raised its stake in Plix maker Satiya
Key facts
- Q1 FY26 consolidated net profit: Rs 513 crore, up 8.2% YoY from Rs 474 crore
- Revenue from operations: Rs 3,259 crore, up 23.31% YoY from Rs 2,643 crore
- Total income: Rs 3,315 crore, including Rs 56 crore other income
- Total expenses: Rs 2,659 crore versus Rs 2,075 crore
- India revenue: Rs 2,495 crore, up 27.17% YoY from Rs 1,962 crore
- International revenue: Rs 764 crore, up 12.91% YoY from Rs 681 crore
- India segment PBT: Rs 469 crore
- International segment PBT: Rs 213 crore
- Marico increased its Satiya Nutraceuticals stake to 60% on a fully diluted basis
Why this matters
Increasing its Plix maker Satiya Nutraceuticals stake to 60% strengthens Marico’s exposure to the high-growth wellness and nutrition category while deepening control over the asset.
What to watch
- Quarterly volume growth versus price-led growth in the India business.
- Copra, edible-oil, crude-linked packaging and freight-cost trends, and their effect on gross margin.
- Advertising and promotion intensity, especially around Plix, Saffola and premium personal-care launches.
- Plix revenue trajectory, profitability and whether consolidation creates dilution or accelerates wellness-category growth.
- Rural demand resilience, urban premiumisation and competitive pricing actions from large FMCG peers.
- International constant-currency growth and currency movements in Bangladesh, Vietnam, MENA and other key markets.
- Increase distribution, marketing and innovation spending behind premium personal care, foods and health-and-wellness portfolios.
- Integrate Satiya Nutraceuticals/Plix more deeply, likely expanding omnichannel distribution, product launches and cross-selling through Marico's consumer base.
- Use selective pricing and pack-size architecture in Parachute and Saffola to protect volume growth while managing commodity-cost inflation.
- Prioritise margin-accretive premium SKUs and international-market execution to narrow the gap between revenue and profit growth.